New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
09:24 EDTTEVA, PRGOPerrigo announces settlement in Proair HFA patent case
Perrigo (PRGO) and its partner, Catalent, announced that they have settled their first to file Hatch Waxman litigation with Teva (TEVA) with respect to a generic version of Proair HFA. Pursuant to the settlement, Perrigo has a limited quantity license to launch a generic version of Proair HFA starting on December 19, 2016 and an unlimited quantity license beginning after June 30, 2018. Proair® HFA indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. Brand sales were approximately $1.4B over the last 52-weeks according to Symphony Health Solutions.
News For PRGO;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 17, 2015
12:56 EDTTEVAFederal Circuit upholds Mylan's patents on Perforomist inhalation solution
Mylan (MYL) announced the United States Court of Appeals for the Federal Circuit upheld the validity and infringement of all four patents asserted by Mylan Specialty, L.P. protecting its Perforomist Inhalation Solution. The Court summarily affirmed the previous decision by the district court against Teva (TEVA). Today's decision prevents Teva from receiving final approval of its ANDA from the FDA prior to expiration of U.S. Patent Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645. Those patents cover Perforomist until they expire in June 2021.
08:12 EDTTEVATeva pullback a buying opportunity, says Leerink
Leerink views yesterday's pullback in shares of Teva after generic Copaxone was approved as a buying opportunity. The firm notes Teva remains confident in its $5 earnings per share floor. Leerink views the company's outlook as "bright" and keeps an Outperform rating on the name.
08:00 EDTTEVATeva patent loss should move management to acquire Mylan, says Cowen
Subscribe for More Information
April 16, 2015
16:02 EDTTEVAOptions Update; April 16, 2015
Subscribe for More Information
15:40 EDTTEVAGeneric Copaxone approval a bit early but expected, says BMO Capital
BMO Capital believes FDA approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone came slightly earlier than the market expected, but the firm added that the generic threat has been well expected. The firm added that it appears Mylan’s (MYL) generic Copaxone hasn't been approved yet, leaving a "legitimate question" about why the FDA approved one generic and not the other. BMO thinks Teva's rate of conversion to the 40mg dose will help retain patients on the Copaxone franchise and it keeps an Outperform rating on Teva shares.
14:12 EDTPRGOPerrigo announces launch of generic version of Kenalog nasal spray
Subscribe for More Information
13:42 EDTTEVATeva shares defended at Evercore ISI
Subscribe for More Information
12:37 EDTTEVAMomenta confirms Glatopa approval, to receive $10M payment
Subscribe for More Information
12:35 EDTTEVASandoz receives FDA approval for Glatopa as generic competitor to Copaxone
Sandoz, a Novartis (NVS) company, announced the U.S. approval of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy. Glatopa, developed in collaboration with Momenta (MNTA) and produced entirely in the U.S., is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS.
12:35 EDTTEVAFDA denies Teva attempt to block generic Copaxone
Subscribe for More Information
10:15 EDTPRGOOptions with decreasing implied volatility
Subscribe for More Information
06:16 EDTTEVAFormer Teva CEO appointed to position of CEO at Ovid Therapeutics
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, appointed Dr. Jeremy Levin as CEO. Levin has served as Chairman of Ovid since 2014 and will continue to serve in this role. Most recently, Levin served as CEO of Teva.
April 15, 2015
19:34 EDTTEVAVIVUS files patent infringement lawsuit against Teva
Subscribe for More Information
09:02 EDTPRGORBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
06:09 EDTPRGOStocks with implied volatility below IV index mean; FXE PRGO
Subscribe for More Information
April 14, 2015
10:50 EDTPRGOOptions with increasing implied volatility
Subscribe for More Information
08:03 EDTTEVATeva, Eagle announce NDA for bendamustine HCI accepted for filing
Subscribe for More Information
April 13, 2015
10:48 EDTPRGOOptions with increasing implied volatility
Options with increasing implied volatility: CLDN WETF EWH FOSL FXI TLM PRGO ATHN SYMC MAC
07:56 EDTPRGO, TEVAMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
06:49 EDTPRGOMylan notifies Perrigo of HSR filing regarding proposed acquisition
Mylan N.V. (MYL) announced that it has provided Perrigo (PRGO) with notice of its filing of the premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use